YARW Yarrow Bioscience, Inc. - Common Stock
YARW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
YARW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount |
|---|---|
| July 24, 2026 | $20.1000 |
YARW Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
2 analysts · 2026-08-15Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-4.00 | $-9.18 | 5.2% |
| Dec. 31, 2025 | $-5.65 | $-9.18 | 3.5% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 14
| Metric | Trend | Q2 2026 |
|---|---|---|
| Revenue | $97.0K | |
| R&D Expense | $788.0K | |
| SG&A Expense | $2M | |
| Operating Expenses | $3M | |
| Operating Income | $-3M | |
| Other Non-op | $203.0K | |
| Pretax Income | $-3M | |
| Income Tax | $0 | |
| Net Income | $-3M | |
| EPS (Basic) | $-3.51 | |
| EPS (Diluted) | $-3.51 | |
| Shares (Basic) | 858,000 | |
| Shares (Diluted) | 858,000 | |
| EBITDA | $-3M |
Balance Sheet 19
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $23M | |
| Short-term Investments | $0 | |
| Prepaid Expense | $601.0K | |
| Current Assets | $24M | |
| PP&E (Net) | $78.0K | |
| PP&E (Gross) | $117.0K | |
| Accum. Depreciation | $39.0K | |
| Total Assets | $24M | |
| Accrued Liabilities | $815.0K | |
| Current Liabilities | $2M | |
| Total Liabilities | $2M | |
| Long-term Debt | $0 | |
| Common Stock | $0 | |
| Paid-in Capital | $786M | |
| Retained Earnings | $-764M | |
| AOCI | $0 | |
| Stockholders' Equity | $22M | |
| Liabilities + Equity | $24M | |
| Shares Outstanding | 668,327 |
Cash Flow 6
| Metric | Trend | Q2 2026 |
|---|---|---|
| D&A | $6.0K | |
| Stock-based Comp | $436.0K | |
| Operating Cash Flow | $-2M | |
| Investing Cash Flow | $300.0K | |
| Financing Cash Flow | $-14.0K | |
| Net Change in Cash | $-2M |
Profitability 7
| Metric | Trend | Q2 2026 |
|---|---|---|
| Operating Margin | -3197.9% | |
| Net Margin | -3100.0% | |
| Pretax Margin | -2988.7% | |
| EBITDA Margin | -3197.9% | |
| ROA | -8.8% | |
| ROE | -9.9% | |
| ROIC | -14.1% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 |
|---|---|---|
| Current Ratio | 15.3 | |
| Quick Ratio | 14.9 |
Efficiency 1
| Metric | Trend | Q2 2026 |
|---|---|---|
| Asset Turnover | 0.0 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 2 insiders · 2 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| David Domzalski | President and CEO | March 17, 2022 A | 1,072,935 | 0 | 0 | $0 |
| Mutya Harsch | Chief Legal Officer and GC | April 6, 2020 F | 170,712 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, OrbiMed Capital GP X LLC, OrbiMed Capital GP X, LP, OrbiMed Genesis GP LLC | Aug. 5, 2026 | 9.97% | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.